# A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

> **NCT01957436** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 1173 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** abiraterone acetate
- **RADIATION:** radiotherapy
- **OTHER:** Androgen Deprivation Therapy
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT01957436
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2013-11-13
- **Primary completion:** 2021-08-18
- **Final completion:** 2032-12
- **Target enrollment:** 1173 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01957436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01957436, "A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01957436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*